All paths of MF lead to inflammation, says Dr Fleischman, and she is committed to exploring the many detours the imbalanced immune system takes in the disease. What is known about the inflammatory milieu in patients with MF is their pro-inflammatory signals become more aggressive and anti-inflammatory responses begin to malfunction. In essence, inflammation strengthens in MF as stopgaps fail, contributing to the complex, heterogeneous phenotype of the disease.
Key inflammatory cytokines, such as TNF-α, IL-1, and IL-6, and the JAK-STAT inflammatory pathway play roles in the pathophysiology of MF. But according to Dr Fleischman, they are just a drop in the bucket.
“The problem goes well beyond individual cytokines and a single JAK pathway. Inflammation requires a whole compilation of cytokines working together, and multiple pathways are engaged. If you only target one, other compensatory pathways could upregulate.”
Inflammation in Myelofibrosis
with Angela Fleischman, MD, PhD University of California Irvine
Exploring the depths of a rare disease
Imagine if we only knew the ocean by its waves, missing all that lingers beneath. How could we possibly know the vastness of the sea by simply perceiving it from the surface? We must dive in and explore the depths. “We must go and see for ourselves,” said Jacques Cousteau, famed oceanic explorer.
Physician-scientist Angela Fleischman follows a similar motto in her work exploring myeloproliferative neoplasms (MPNs). “There is a difference between what we know on the surface and what’s going on underneath,” she says.
Mitigating symptoms, reducing spleen volume, and managing through both disease- and therapy-related cytopenias, have risen to the top as key components in the care of patients with myelofibrosis (MF). But Dr Fleischman says just focusing on these factors undermines the complexity of the disease—and the root of its pathogenesis.
What lies below, says Dr Fleischman, is chronic inflammation. “Inflammation touches everything about MF. It’s not just about the JAK2 clone.” In fact, she questions whether the mutation is a consequence of the disease rather than the source. “In my mind, the bigger issue is why the clone arose in the first place. If you were to somehow get rid of the mutation in a patient with MF, you would still be left with the problem.”
For Dr Fleischman, inflammation is clearly a driver, if not the driver, of MF pathogenesis, and potentially disease progression. When it comes to caring for patients with MF, she urges a more comprehensive approach. “Patients really need more,” she says. “Improving symptoms improves quality of life, and that is important. But patients also need things like blocking the tendency to progress to an acute leukemia, reducing fibrosis, and improving overall survival.”
Through her research, Dr Fleischman is helping to make way for a better future for patients with MF by shedding light on the expansive inflammatory landscape that churns the waves of the disease.
The many pathways
to inflammation in MF
Traveling between worlds as a physician-scientist
From bench to bedside and back again, Dr Fleischman traverses disciplines searching for the source of chronic inflammation in MF. On Mondays, she sees patients in the clinic; the rest of the week, she conducts preclinical studies in her lab— The Fleischman Lab at UC Irvine.
Navigating these distinct fields helps her see the bigger picture, she says. “Because I’m the same person working on both ends of the spectrum, I can see tiny details and entertain curiosities between the two.”
Patients offer her deep insight into the disease, says Dr Fleischman. In the clinic, she’s able to see how MPNs progress firsthand. And while she relies on lab reports, bone marrow biopsies, and spleen size to inform her conversations with patients, she digs deeper to pair the individual’s physiology with their philosophy on managing their disease.
In turn, Fleischman uses the outcomes from her laboratory studies as a north star to guide the development of patient studies in the clinic. In essence, her work encompasses a cooperative input/output system that helps identify common threads in inflammation and MF that wouldn’t otherwise connect.
And she wouldn’t have it any other way. “You know, research is not just some people working in a lab. Research involves people with MPNs and researchers working together towards a common goal.” All the little pieces of knowledge are coming together, she says, to further understand the depths of the disease.
“I know more about MPNs than I did a year ago, a lot more than I did 5 years ago, and hopefully 5 years from now, I’ll understand more than I do today.”
Dr Fleischman adds, “Hopefully sometime during my lifetime things will all fall into place.”
